The MissionAD study for early stages of Alzheimer’s disease…Currently Enrolling

Description

The MissionAD study program is a clinical research program testing an investigational drug for the early stages of Alzheimer’s disease. (“Investigational” means the drug isn’t yet approved for use by the public.) Doctors are studying this investigational drug to make sure it is safe and to see if it may help people with Alzheimer’s disease in the future.

People who qualify for this research study may receive:

  • Investigational drug
  • Study-related care from a local study doctor
  • Reimbursement for travel expenses

To qualify, participants must:

  • Be 50 to 85 years of age
  • Be experiencing noticeable changes in memory or thinking
  • Have a regular informant/study partner available

Doctors will also check other requirements to confirm that you qualify for this study.

How can I get started?

  • Step 1: Contact our study coordinator. The study coordinator will give you information about the study and help determine if you might qualify.
  • Step 2: Give informed consent. A study doctor will explain that study procedures and its possible benefits and risks. The study doctor will also answer any questions you might have. To join our study, you must read and sign an informed consent document to show that you understand the study and what’s required.
  • Step 3: Find out if you are eligible. The study staff will ask some health questions and may do some medical evaluation to make sure that you meet the requirements for the study.
  • Step 4: Participate. If eligible, you’ll enter the study for approximately 2 years and make regular visits to the study doctor’s office during that time. The staff will work with you to find convenient times for these visits.

For more information about this research study call: (561) 282-5538 or email using form below

MissionAD Study for early Alzheimer's disease

About the Author:Dr. Michael Tuchman